vx15/2503
mAbexperimental
Clinical trial activity
8 trials · 22 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2011 (NCT01313065)
Timeline
Indications
Mechanism of action
- Semaphorin-4DINHIBITOR
inhibitor - sema4d
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- vx15/2503
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03690986 | Phase 1 | Sep 1, 2019 | Emory University, Vaccinex Inc. |
| NCT03769155 | Phase 1 | Dec 13, 2018 | Bristol-Myers Squibb, Emory University, National Cancer Institute (NCI), National Institutes of Health (NIH), Vaccinex Inc. |
| NCT03425461 | Phase 1 | Jun 14, 2018 | Bristol-Myers Squibb, National Cancer Institute (NCI), University of California, Los Angeles, Vaccinex Inc. |
| NCT03373188 | Phase 1 | Dec 15, 2017 | Emory University, Vaccinex Inc. |
| NCT03268057 | Phase 1/Phase 2 (Phase 2) | Oct 5, 2017 | Merck KGaA, Vaccinex Inc. |
| NCT02481674 | Phase 2 | Jul 1, 2015 | Feinstein Institute for Medical Research, Huntington Study Group, Vaccinex Inc. |
| NCT01764737 | Phase 1 | Dec 1, 2012 | Indiana University, MS Center of Northeastern New York, North Central Neurology Associates, PC, Pharmaceutical Research Associates, Inc. (PRA), The Neurological Institute, PA, University of Colorado, University of Kansas, University of Rochester, University of Washington, Vaccinex Inc., Wayne State University |
| NCT01313065 | Phase 1 | Jan 1, 2011 | PPD, South Texas Accelerated Research Therapeutics, TGen Drug Development, Vaccinex Inc. |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (22)
22 organizations
Page 1 / 2